Suchergebnisse - "O3J8G9O825"

PubPharm (5.526)

91

Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing : a multicenter retrospective cohort study

enthalten in: BMC infectious diseases | 2024

von Han, X. | Gao, D. | Li, C. | +18

92

PBPK Modeling of PAXLOVIDTM : Incorporating Rotamer Conversion Kinetics to Advanced Dissolution and Absorption Model

enthalten in: Journal of pharmaceutical sciences | 2024

von Jaini, R. | Lin, J. | Di, L. | +1

93

Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults

enthalten in: British journal of clinical pharmacology | 2024

von Zhang, Y. | Joshi, S. | Yazdani, P. | +6

94

A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir

enthalten in: Clinical pharmacokinetics | 2024

von Gerhart, J. | Cox, D. | Singh, R. | +6

95

Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19 : a retrospective observational study

enthalten in: BMC infectious diseases | 2024

von Zhou, Z. | Zheng, H. | Xiao, G. | +3

96

Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients

enthalten in: BMC infectious diseases | 2024

von Su, P. | Yang, C. | Wang, X.

97

Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania

enthalten in: PloS one | 2024

von Jiwa, N. | Ketang'enyi, E. | Nganyanyuka, K. | +12

98

Adverse Events of SARS-CoV-2 Therapy : A Pharmacovigilance Study of the FAERS Database

enthalten in: The Annals of pharmacotherapy | 2024

von Pannu, V. | Udongwo, N. | Imburgio, S. | +10

99

Association Between Paxlovid and Mortality Rates in Critically Ill Patients With COVID-19 Receiving Invasive Mechanical Ventilation : A Retrospective Cohort Study

enthalten in: Chest | 2024

von Yang, M. | Jiang, L. | Xu, L. | +1

100

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV) : an open-label, phase 2, randomised, controlled, adaptive trial

enthalten in: The Lancet. Infectious diseases | 2024

von Schilling, W. | Jittamala, P. | Watson, J. | +89

ErratumIn: Lancet Infect Dis. 2023 Dec;23(12):e511. - PMID 37839427